Strategic partnerships Deep Bio has a track record of collaborating with leading pathology and AI players (PathAI, Roche Navify, CancerX) and participates in major oncology forums (AACR). A sales opportunity exists in formalizing co-development, integration, or reseller agreements with digital pathology platforms and diagnostic workflow providers to expand market access.

Enterprise AI healthcare With revenue in the mid five-figures to low six-figures and growing capabilities in AI-powered SaMDs for cancer diagnostics, there is potential to target tiered healthcare systems and mid-market hospitals seeking scalable, compliant AI diagnostic software and IVD SaMDs to enhance diagnostic accuracy.

Global cloud stack Utilizing AWS, Google Cloud, and Microsoft Azure indicates a flexible, multi-cloud deployment model. This positions Deep Bio to sell cross-cloud integration services, data migration, and secured AI model deployment support for large health networks with diverse cloud ecosystems.

Regulatory-ready roadmap As a provider of IVD SaMDs with notable awards and clinical validation, leverage this credibility to approach hospital systems and regional regulators about expanded indications, real-world evidence programs, and reimbursement-ready solutions.

Growth through academia Active engagement in research at major conferences and collaborations suggests opportunities to partner with academic medical centers for pilot deployments, clinical studies, and data-collaboration projects that demonstrate ROI and drive adoption.